| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.79(B) |
| Last
Volume: |
2,475,481 |
Avg
Vol: |
2,443,625 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
66,225 |
325,783 |
532,046 |
1,028,448 |
| Total Sell Value |
$1,469,691 |
$7,234,582 |
$11,431,100 |
$20,278,991 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
2 |
8 |
12 |
26 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wyszomierski Jack L |
Director |
– • – |
2022-04-04 |
4 |
OE |
$3.13 |
$125,200 |
D/D |
40,000 |
279,888 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-04-01 |
4 |
AS |
$23.00 |
$230,000 |
D/D |
(10,000) |
269,191 |
|
-16% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-04-01 |
4 |
OE |
$6.21 |
$62,100 |
D/D |
10,000 |
279,191 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-03-31 |
4 |
AS |
$22.43 |
$224,300 |
D/D |
(10,000) |
269,191 |
|
-14% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-03-31 |
4 |
OE |
$6.21 |
$62,100 |
D/D |
10,000 |
279,191 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-03-29 |
4 |
AS |
$22.00 |
$292,226 |
D/D |
(13,283) |
605,236 |
|
-2% |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-03-28 |
4 |
AS |
$22.00 |
$103,774 |
D/D |
(4,717) |
618,519 |
|
-1% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
70,715 |
269,191 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
59,490 |
402,485 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
67,875 |
623,236 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
270,415 |
399,271 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2022-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,985 |
429,833 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2022-03-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
50,000 |
1,196,316 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2022-03-01 |
4 |
AS |
$21.00 |
$447,321 |
D/D |
(21,301) |
31,417 |
|
-1% |
|
| Garber Alan M |
Director |
– • – |
2022-03-01 |
4 |
OE |
$3.13 |
$125,200 |
D/D |
40,000 |
52,718 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-02-25 |
4 |
S |
$19.53 |
$610,078 |
D/D |
(31,238) |
198,476 |
|
-8% |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2022-02-24 |
4 |
AS |
$20.00 |
$360,000 |
D/D |
(18,000) |
555,361 |
|
7% |
|
| Feldbaum Carl B |
Director |
– • – |
2022-02-22 |
4 |
S |
$19.49 |
$389,800 |
D/D |
(20,000) |
8,521 |
|
-10% |
|
| Feldbaum Carl B |
Director |
– • – |
2022-02-22 |
4 |
OE |
$3.13 |
$62,600 |
D/D |
20,000 |
28,521 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2022-02-22 |
4 |
S |
$19.56 |
$1,653,113 |
D/D |
(84,515) |
1,220,036 |
|
-10% |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2022-02-15 |
4 |
D |
$18.59 |
$227,281 |
D/D |
(12,226) |
573,361 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2022-02-15 |
4 |
D |
$18.59 |
$1,211,083 |
D/D |
(65,147) |
128,856 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2022-02-15 |
4 |
D |
$18.59 |
$375,090 |
D/D |
(20,177) |
342,995 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2022-02-15 |
4 |
D |
$18.59 |
$340,699 |
D/D |
(18,327) |
353,848 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-02-15 |
4 |
D |
$18.59 |
$288,647 |
D/D |
(15,527) |
229,714 |
|
- |
|
985 Records found
|
|
Page 7 of 40 |
|
|
